Glenmark gets first generic approvals for Advair MDI
This article was originally published in Scrip
Executive Summary
While a recent FDA draft guidance raised hopes that cut-price versions of GlaxoSmithKline's blockbuster asthma/COPD product Advair (fluticasone/salmeterol) may arrive earlier than anticipated in the US, the Indian company, Glenmark, has received what's perhaps the first approval for a generic Advair MDI (metered-dose inhaler) in Mexico and the Philippines.
You may also be interested in...
Glenmark Ups Respiratory Play But Is The Digihaler Disruptive?
Glenmark Pharmaceuticals Ltd., which is building its global respiratory play, appears to be betting big on its new next-generation digital inhaler that the India firm underscores is meaningful innovation that patients can afford. The jury, though, appears to be still out on whether India’s first digital dose inhaler (DDI) can help move the adherence needle.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet